136 related articles for article (PubMed ID: 1376476)
1. [Use of octreotide in the treatment of digestive endocrine tumors. A French multicenter study].
Blanchin M; James-Deidier A; Chaumet-Riffaud PD; Chayvialle JA
Presse Med; 1992 Apr; 21(15):697-702. PubMed ID: 1376476
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
Arnold R; Neuhaus C; Trautmann ME
Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
[No Abstract] [Full Text] [Related]
3. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
Arnold R; Frank M; Kajdan U
Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
[TBL] [Abstract][Full Text] [Related]
4. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors.
Trautmann ME; Neuhaus C; Lenze H; Benning R; Benning M; Dennler HJ; Bruns C; Joseph K; Arnold R
Horm Metab Res Suppl; 1993; 27():24-7. PubMed ID: 8392487
[No Abstract] [Full Text] [Related]
5. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
[TBL] [Abstract][Full Text] [Related]
6. Iodine-123-Tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide.
Nocaudie-Calzada M; Huglo D; Deveaux M; Carnaille B; Proye C; Marchandise X
J Nucl Med; 1994 Jan; 35(1):57-62. PubMed ID: 8271061
[TBL] [Abstract][Full Text] [Related]
7. [Somatostatin analogue in the treatment of neuroendocrine gut tumors].
Ben Yosef R; Glaser B; Catane R
Harefuah; 1990 Jul; 119(1-2):15-8. PubMed ID: 2172125
[TBL] [Abstract][Full Text] [Related]
8. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors.
Maton PN; Gardner JD; Jensen RT
Dig Dis Sci; 1989 Mar; 34(3 Suppl):28S-39S. PubMed ID: 2537716
[TBL] [Abstract][Full Text] [Related]
9. Use of octreotide in the treatment of digestive neuroendocrine tumours. Seven year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma.
Fiasse R; Pauwels S; Rahier J; Jamar F; Ketelslegers JM; Hassoun A; de Longueville M
Acta Gastroenterol Belg; 1993; 56(3-4):279-91. PubMed ID: 8266771
[TBL] [Abstract][Full Text] [Related]
10. [The somatostatin analog SMS 201-995 in long-term treatment of vipoma].
Christensen C
Ugeskr Laeger; 1990 Dec; 152(51):3851-3. PubMed ID: 2177234
[TBL] [Abstract][Full Text] [Related]
11. Future medical prospects for Sandostatin.
Harris AG
Z Gastroenterol; 1990 Sep; 28 Suppl 2():55-60. PubMed ID: 1980778
[TBL] [Abstract][Full Text] [Related]
12. Effects of sandostatin on neuroendocrine tumours of the gastrointestinal system.
Buchanan KD
Recent Results Cancer Res; 1993; 129():45-55. PubMed ID: 8394596
[TBL] [Abstract][Full Text] [Related]
13. Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
Tomassetti P; Migliori M; Gullo L
Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors.
Ronchi CL; Peracchi M; Corbetta S; Massironi S; Ciafardini C; Conte D; Beck-Peccoz P; Spada A
J Endocrinol Invest; 2007 Mar; 30(3):241-6. PubMed ID: 17505159
[TBL] [Abstract][Full Text] [Related]
15. Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995.
Glaser B; Rösler A; Halperin Y
Isr J Med Sci; 1990 Jan; 26(1):16-9. PubMed ID: 2155884
[TBL] [Abstract][Full Text] [Related]
16. [Mixed endocrine tumor of the pancreas (vipoma, glucagonoma). Treatment by somatostatin followed by one of its long-acting analogs].
Kaloustian E; Guillauseau PJ; Chayvialle JA; Veyssier P; Lallement PY; Latrive JP; Zylberait D; Lubetzki J
Presse Med; 1987 Dec; 16(44):2217-20. PubMed ID: 2893369
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
Williams G; Anderson JV; Williams SJ; Bloom SR
Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
[TBL] [Abstract][Full Text] [Related]
18. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors.
Moattari AR; Deftos LJ; Vinik AI
J Clin Endocrinol Metab; 1989 Oct; 69(4):902-5. PubMed ID: 2778040
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201-995.
Anderson JV; Bloom SR
Scand J Gastroenterol Suppl; 1986; 119():115-28. PubMed ID: 2876495
[TBL] [Abstract][Full Text] [Related]
20. Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis.
Burgess JR; Greenaway TM; Parameswaran V; Shepherd JJ
Cancer; 1999 Nov; 86(10):2154-9. PubMed ID: 10570446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
